Edith A Perez

List of Publications by Year
in descending order

29 papers	6,663 citations	279487 23 h-index	454577 30 g-index
32 all docs	32 docs citations	32 times ranked	9410 citing authors

#	Article	IF	Citations
1	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology, 2013, 31, 3997-4013.	0.8	3,276
2	Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology, 2014, 32, 3744-3752.	0.8	771
3	Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. Journal of Clinical Oncology, 2015, 33, 594-601.	0.8	365
4	Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2â€“Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. Journal of Clinical Oncology, 2017, 35, 141-148.	0.8	327
5	HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology, 2010, 28, 4307-4315.	0.8	216
6	Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). Journal of Clinical Oncology, 2015, 33, 2361-2369.	0.8	197
7	Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. JAMA Oncology, 2016, 2, 56.	3.4	183
8	Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology, 2015, 33, 701-708.	0.8	171
9	Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. Journal of Clinical Oncology, 2015, 33, 2353-2360.	0.8	167
10	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 2100-2108.	0.8	165
11	Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial. Journal of Clinical Oncology, 2013, 31, 2115-2122.	0.8	104
12	Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Early Breast Cancer and Tumors â‰¥ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. Journal of Clinical Oncology, 2015, 33, 2600-2608.	0.8	91
13	Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Research and Treatment, 2009, 114, 195-201.	1.1	83
14	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). Npj Breast Cancer, 2016, 2, .	2.3	80
15	Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance). Journal of Clinical Oncology, 2014, 32, 2311-2317.	0.8	70
16	Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2â€“positive advanced breast cancer: Final results from MARIANNE. Cancer, 2019, 125, 3974-3984.	2.0	67
17	Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Research, 2016, 18, 126.	2.2	58
18	Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Breast Cancer Research, 2014, 16, R50.	2.2	49

#	Article	IF	Citations
19	Current and emerging targeted therapies for metastatic breast cancer. Cancer, 2012, 118, 3014-3025.	2.0	42
20	Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine Â± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. BMC Cancer, 2019, 19, 517.	1.1	42
21	Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring anERBB2S310F Mutation. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1066-1070.	2.3	31
22	Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial. Journal of the National Cancer Institute, 2017, 109, djw207.	3.0	26
23	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. Journal of the National Cancer Institute, 2016, 108, djw037.	3.0	24
24	Biomarker Testing for Breast, Lung, and Gastroesophageal Cancers at NCI Designated Cancer Centers. Journal of the National Cancer Institute, 2014, 106, .	3.0	18
25	Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma. Cancer, 1997, 80, 676-680.	2.0	15
26	Dual HER2 blockade: preclinical and clinical data. Breast Cancer Research, 2014, 16, 419.	2.2	11
27	The Globalization of Cooperative Groups. Seminars in Oncology, 2015, 42, 693-712.	0.8	6
28	Management of Bone Metastases in Advanced Breast Cancer. Cancer Control, 1999, 6, 28-31.	0.7	2
29	Adjuvant Chemotherapy: Controversies and the Role of Taxanes. Breast Journal, 2003, 9, S25-S28.	0.4	2